

# Olivia M Dean

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3724961/publications.pdf>

Version: 2024-02-01

123  
papers

7,737  
citations

81743

39  
h-index

53109

85  
g-index

125  
all docs

125  
docs citations

125  
times ranked

9233  
citing authors

#	ARTICLE	IF	CITATIONS
1	Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. <i>International Journal of Neuropsychopharmacology</i> , 2008, 11, 851-76.	1.0	821
2	The chemistry and biological activities of N-acetylcysteine. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2013, 1830, 4117-4129.	1.1	620
3	N-Acetyl Cysteine as a Glutathione Precursor for Schizophreniaâ€”A Double-Blind, Randomized, Placebo-Controlled Trial. <i>Biological Psychiatry</i> , 2008, 64, 361-368.	0.7	489
4	N-Acetyl Cysteine for Depressive Symptoms in Bipolar Disorderâ€”A Double-Blind Randomized Placebo-Controlled Trial. <i>Biological Psychiatry</i> , 2008, 64, 468-475.	0.7	452
5	N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. <i>Journal of Psychiatry and Neuroscience</i> , 2011, 36, 78-86.	1.4	373
6	The promise of N-acetylcysteine in neuropsychiatry. <i>Trends in Pharmacological Sciences</i> , 2013, 34, 167-177.	4.0	359
7	Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 55, 294-321.	2.9	350
8	<i>N</i>-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 1955-1962.	1.4	335
9	Oxidative & nitrosative stress in depression: Why so much stress?. <i>Neuroscience and Biobehavioral Reviews</i> , 2014, 45, 46-62.	2.9	324
10	A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 65, 185-194.	2.9	256
11	Post-Operative Cognitive Dysfunction: An exploration of the inflammatory hypothesis and novel therapies. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 84, 116-133.	2.9	210
12	Glutathione: a novel treatment target in psychiatry. <i>Trends in Pharmacological Sciences</i> , 2008, 29, 346-351.	4.0	166
13	The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: An open label trial. <i>Journal of Affective Disorders</i> , 2011, 135, 389-394.	2.0	162
14	A model of the mitochondrial basis of bipolar disorder. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 74, 1-20.	2.9	118
15	Minocycline. <i>CNS Drugs</i> , 2012, 26, 391-401.	2.7	117
16	N-acetylcysteine for major depressive episodes in bipolar disorder. <i>Revista Brasileira De Psiquiatria</i> , 2011, 33, 374-378.	0.9	99
17	&lt;em&gt;N&lt;/em&gt;-Acetylcysteine in Depressive Symptoms and Functionality. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e457-e466.	1.1	93
18	Putative neuroprotective agents in neuropsychiatric disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 42, 135-145.	2.5	88

#	ARTICLE	IF	CITATIONS
19	The effect of N-acetylcysteine (NAC) on human cognition – A systematic review. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 78, 44-56.	2.9	82
20	Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomized placebo controlled trial. <i>BMC Medicine</i> , 2012, 10, 91.	2.3	81
21	N-Acetyl Cysteine in the Treatment of Obsessive Compulsive and Related Disorders: A Systematic Review. <i>Clinical Psychopharmacology and Neuroscience</i> , 2015, 13, 12-24.	0.9	78
22	N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats: Relevance to schizophrenia and bipolar disorder. <i>Neuroscience Letters</i> , 2011, 499, 149-153.	1.0	75
23	Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 829-840.	1.3	75
24	A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo. <i>BMC Medicine</i> , 2019, 17, 18.	2.3	73
25	The effect of blueberry interventions on cognitive performance and mood: A systematic review of randomized controlled trials. <i>Brain, Behavior, and Immunity</i> , 2020, 85, 96-105.	2.0	67
26	Glutathione depletion in the brain disrupts short-term spatial memory in the Y-maze in rats and mice. <i>Behavioural Brain Research</i> , 2009, 198, 258-262.	1.2	63
27	The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial. <i>Lancet Psychiatry</i> , 2019, 6, 735-744.	3.7	63
28	N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study. <i>CNS Drugs</i> , 2015, 29, 801-809.	2.7	59
29	A Review of the Theoretical and Biological Understanding of the Nocebo and Placebo Phenomena. <i>Clinical Therapeutics</i> , 2017, 39, 469-476.	1.1	59
30	Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis. <i>Nutrition Reviews</i> , 2019, 77, 557-571.	2.6	59
31	Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 453-466.	1.3	58
32	Effects of N-acetyl-cysteine treatment on glutathione depletion and a short-term spatial memory deficit in 2-cyclohexene-1-one-treated rats. <i>European Journal of Pharmacology</i> , 2010, 649, 224-228.	1.7	54
33	Nail-Biting Stuff? The Effect of N-acetyl Cysteine on Nail-Biting. <i>CNS Spectrums</i> , 2009, 14, 357-360.	0.7	53
34	A preliminary investigation on the efficacy of N-acetyl cysteine for mania or hypomania. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 564-568.	1.3	50
35	Prebiotics, probiotics, fermented foods and cognitive outcomes: A meta-analysis of randomized controlled trials. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 118, 472-484.	2.9	50
36	Tobacco Use in Bipolar Disorder. <i>Clinical Psychopharmacology and Neuroscience</i> , 2015, 13, 1-11.	0.9	49

#	ARTICLE	IF	CITATIONS
37	Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 424-455.	1.3	49
38	A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 241-249.	1.3	48
39	Effects of N-acetyl cysteine on cognitive function in bipolar disorder. <i>Psychiatry and Clinical Neurosciences</i> , 2012, 66, 514-517.	1.0	45
40	Prebiotic and probiotic supplementation and the tryptophan-kynurenine pathway: A systematic review and meta analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 123, 1-13.	2.9	39
41	Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression. <i>Revista Brasileira De Psiquiatria</i> , 2015, 37, 03-12.	0.9	38
42	Oxidative pathways as a drug target for the treatment of autism. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 1301-1310.	1.5	35
43	N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms. <i>BMC Psychiatry</i> , 2016, 16, 320.	1.1	34
44	Beyond the therapeutic shackles of the monoamines: New mechanisms in bipolar disorder biology. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 72, 73-86.	2.5	31
45	Towards stage specific treatments: Effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2015, 57, 69-75.	2.5	29
46	Improvement of cognitive function in schizophrenia with N-acetylcysteine: A theoretical review. <i>Nutritional Neuroscience</i> , 2020, 23, 139-148.	1.5	29
47	Qualitative Methods in Early-Phase Drug Trials. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 909-913.	1.1	29
48	Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 681-697.	1.0	28
49	The use of a gene expression signature and connectivity map to repurpose drugs for bipolar disorder. <i>World Journal of Biological Psychiatry</i> , 2020, 21, 775-783.	1.3	27
50	A potential role for N-acetylcysteine in the management of methamphetamine dependence. <i>Drug and Alcohol Review</i> , 2017, 36, 153-159.	1.1	25
51	Adjunctive N-acetylcysteine in depression: exploration of interleukin-6, C-reactive protein and brain-derived neurotrophic factor. <i>Acta Neuropsychiatrica</i> , 2017, 29, 337-346.	1.0	25
52	An update on adjunctive treatment options for bipolar disorder. <i>Bipolar Disorders</i> , 2018, 20, 87-96.	1.1	25
53	Insight in substance use disorder: A systematic review of the literature. <i>Addictive Behaviors</i> , 2020, 111, 106549.	1.7	25
54	Garcinia mangostana Linn displays antidepressant-like and pro-cognitive effects in a genetic animal model of depression: a bio-behavioral study in the Flinders Sensitive Line rat. <i>Metabolic Brain Disease</i> , 2018, 33, 467-480.	1.4	24

#	ARTICLE	IF	CITATIONS
55	Metabolite profiles in the anterior cingulate cortex of depressed patients differentiate those taking N-acetyl-cysteine versus placebo. Australian and New Zealand Journal of Psychiatry, 2013, 47, 347-354.	1.3	23
56	Relationships Between Different Dimensions of Social Support and Suicidal Ideation in Young People with Major Depressive Disorder. Journal of Affective Disorders, 2021, 281, 714-720.	2.0	21
57	Translating the Rosetta Stone of N-Acetylcysteine. Biological Psychiatry, 2012, 71, 935-936.	0.7	20
58	Mechanisms Underpinning the Polypharmacy Effects of Medications in Psychiatry. International Journal of Neuropsychopharmacology, 2018, 21, 582-591.	1.0	19
59	Effect of Sodium Benzoate vs Placebo Among Individuals With Early Psychosis. JAMA Network Open, 2020, 3, e2024335.	2.8	19
60	The Australian Genetics of Depression Study: New Risk Loci and Dissecting Heterogeneity Between Subtypes. Biological Psychiatry, 2022, 92, 227-235.	0.7	18
61	Mediator effects of parameters of inflammation and neurogenesis from a N-acetyl cysteine clinical-trial for bipolar depression. Acta Neuropsychiatrica, 2018, 30, 334-341.	1.0	16
62	The Therapeutic Potential of Mangosteen Pericarp as an Adjunctive Therapy for Bipolar Disorder and Schizophrenia. Frontiers in Psychiatry, 2019, 10, 115.	1.3	16
63	Minocycline as adjunctive treatment for major depressive disorder: Pooled data from two randomized controlled trials. Australian and New Zealand Journal of Psychiatry, 2021, 55, 784-798.	1.3	16
64	Interaction of glutathione depletion and psychotropic drug treatment in prepulse inhibition in rats and mice. Pharmacology Biochemistry and Behavior, 2010, 97, 293-300.	1.3	15
65	Youth Depression Alleviation Augmentation with an anti-inflammatory agent (YoDA): protocol and rationale for a placebo-controlled randomized trial of rosuvastatin and aspirin. Microbial Biotechnology, 2018, 12, 45-54.	0.9	15
66	Statins: Neurobiological underpinnings and mechanisms in mood disorders. Neuroscience and Biobehavioral Reviews, 2021, 128, 693-708.	2.9	15
67	A study protocol for the N-ICE trial: A randomised double-blind placebo-controlled study of the safety and efficacy of N-acetyl-cysteine (NAC) as a pharmacotherapy for methamphetamine dependence. Trials, 2019, 20, 325.	0.7	14
68	A novel way to quantify schizophrenia symptoms in clinical trials. European Journal of Clinical Investigation, 2021, 51, e13398.	1.7	13
69	N-acetylcysteine (NAC) for methamphetamine dependence: A randomised controlled trial. EClinicalMedicine, 2021, 38, 101005.	3.2	12
70	Benefits of adjunctive N-acetylcysteine in a sub-group of clozapine-treated individuals diagnosed with schizophrenia. Psychiatry Research, 2015, 230, 982-983.	1.7	11
71	The efficacy of sodium benzoate as an adjunctive treatment in early psychosis - CADENCE-BZ: study protocol for a randomized controlled trial. Trials, 2017, 18, 165.	0.7	11
72	The effect of emerging nutraceutical interventions for clinical and biological outcomes in multiple sclerosis: A systematic review. Multiple Sclerosis and Related Disorders, 2020, 37, 101486.	0.9	11

#	ARTICLE	IF	CITATIONS
73	Diet quality, dietary inflammatory index and body mass index as predictors of response to adjunctive N-acetylcysteine and mitochondrial agents in adults with bipolar disorder: A sub-study of a randomised placebo-controlled trial. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 159-172.	1.3	11
74	A Systematic Review of Nutraceuticals for the Treatment of Bipolar Disorder. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 262-273.	0.9	11
75	Cognition-immune interactions between executive function and working memory, tumour necrosis factor-alpha (TNF-alpha) and soluble TNF receptors (sTNFR1 and sTNFR2) in bipolar disorder. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 67-77.	1.3	11
76	Transcriptional Modulation of the Hippo Signaling Pathway by Drugs Used to Treat Bipolar Disorder and Schizophrenia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7164.	1.8	11
77	Future Directions for Pharmacotherapies for Treatment-resistant Bipolar Disorder. <i>Current Neuropharmacology</i> , 2015, 13, 656-662.	1.4	11
78	Modulation of high fat diet-induced microbiome changes, but not behaviour, by minocycline. <i>Brain, Behavior, and Immunity</i> , 2019, 82, 309-318.	2.0	10
79	Physical Activity as a Predictor of Clinical Trial Outcomes in Bipolar Depression: A Subanalysis of a Mitochondrial-Enhancing Nutraceutical Randomized Controlled Trial. <i>Canadian Journal of Psychiatry</i> , 2020, 65, 306-318.	0.9	9
80	Anti-inflammatory treatment of bipolar depression: promise and disappointment. <i>Lancet Psychiatry</i> , 2020, 7, 467-468.	3.7	9
81	Studies on Haloperidol and Adjunctive $\hat{\pm}$ -Mangostin or Raw <i>Garcinia mangostana</i> Linn Pericarp on Bio-Behavioral Markers in an Immune-Inflammatory Model of Schizophrenia in Male Rats. <i>Frontiers in Psychiatry</i> , 2020, 11, 121.	1.3	9
82	Systematic review and meta-analysis of the role of personality disorder in randomised controlled trials of pharmacological interventions for adults with mood disorders. <i>Journal of Affective Disorders</i> , 2021, 279, 711-721.	2.0	9
83	The influence of childhood trauma on the treatment outcomes of pharmacological and/or psychological interventions for adolescents and adults with bipolar disorder: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2022, 296, 350-362.	2.0	9
84	Childhood trauma and treatment outcomes during mood-stabilising treatment with lithium or quetiapine among outpatients with bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2022, 145, 615-627.	2.2	9
85	Attachment insecurity partially mediates the relationship between childhood trauma and depression severity in bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2022, 145, 591-603.	2.2	9
86	Participant Characteristics as Modifiers of Response to N-Acetyl Cysteine (NAC) in Obsessive-Compulsive Disorder. <i>Clinical Psychological Science</i> , 2016, 4, 1104-1111.	2.4	8
87	N-acetylcysteine for cessation of tobacco smoking: rationale and study protocol for a randomised controlled trial. <i>Trials</i> , 2019, 20, 555.	0.7	8
88	Efficacy of adjunctive <i>Garcinia mangostana</i> Linn (mangosteen) pericarp for bipolar depression: study protocol for a proof-of-concept trial. <i>Revista Brasileira De Psiquiatria</i> , 2019, 41, 245-253.	0.9	8
89	Clinical and demographic characteristics of people who smoke versus inject crystalline methamphetamine in Australia: Findings from a pharmacotherapy trial. <i>Drug and Alcohol Review</i> , 2021, 40, 1249-1255.	1.1	8
90	Biological Mechanism(s) Underpinning the Association between Antipsychotic Drugs and Weight Gain. <i>Journal of Clinical Medicine</i> , 2021, 10, 4095.	1.0	8

#	ARTICLE	IF	CITATIONS
91	Effects of Psychotropic Drugs on Ribosomal Genes and Protein Synthesis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7180.	1.8	8
92	Dimensions of improvement in a clinical trial of N-acetyl cysteine for bipolar disorder. <i>Acta Neuropsychiatrica</i> , 2011, 23, 87-88.	1.0	7
93	Personality disorder and functioning in major depressive disorder: a nested study within a randomized controlled trial. <i>Revista Brasileira De Psiquiatria</i> , 2020, 42, 14-21.	0.9	7
94	Personality disorder increases risk of low quality of life among women with mental state disorders. <i>Comprehensive Psychiatry</i> , 2020, 102, 152193.	1.5	7
95	Co-Expression Networks Unveiled Long Non-Coding RNAs as Molecular Targets of Drugs Used to Treat Bipolar Disorder. <i>Frontiers in Pharmacology</i> , 2022, 13, 873271.	1.6	7
96	Exploring interleukin-6, lipopolysaccharide-binding protein and brain-derived neurotrophic factor following 12 weeks of adjunctive minocycline treatment for depression. <i>Acta Neuropsychiatrica</i> , 2022, 34, 220-227.	1.0	7
97	Measuring cognitive insight in people with problematic substance use: An exploration of the factor validity of the Beck Cognitive Insight Scale. <i>Drug and Alcohol Review</i> , 2019, 38, 622-629.	1.1	6
98	Drugs used in the treatment of bipolar disorder and their effects on cholesterol biosynthesis – A possible therapeutic mechanism. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 766-777.	1.3	5
99	Protocol and Rationale: A 24-week Double-blind, Randomized, Placebo Controlled Trial of the Efficacy of Adjunctive <i>Garcinia mangostana</i> Linn. (Mangosteen) Pericarp for Schizophrenia. <i>Clinical Psychopharmacology and Neuroscience</i> , 2019, 17, 297-307.	0.9	5
100	Nutraceuticals and nutritional supplements for the treatment of bipolar disorder: protocol for a systematic review. <i>BMJ Open</i> , 2019, 9, e25640.	0.8	5
101	Role of personality disorder in randomised controlled trials of pharmacological interventions for adults with mood disorders: a protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2019, 9, e25145.	0.8	5
102	Modeling psychological function in patients with schizophrenia with the PANSS: an international multi-center study. <i>CNS Spectrums</i> , 2021, 26, 290-298.	0.7	5
103	N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 117, 110550.	2.5	5
104	The evolution of clinical trials in response to COVID-19. <i>Medical Journal of Australia</i> , 2021, 214, 332.	0.8	4
105	Treatment of Refractory Obsessive-Compulsive Disorder with Nutraceuticals (TRON): A 20-week, open label pilot study. <i>CNS Spectrums</i> , 2021, , 1-35.	0.7	4
106	Dietary quality and nutrient intake in adults with obsessive-compulsive disorder. <i>BJPsych Open</i> , 2021, 7, .	0.3	4
107	Effect of Glucocorticoid and 11 $\beta$ -Hydroxysteroid-Dehydrogenase Type 1 (11 $\beta$ -HSD1) in Neurological and Psychiatric Disorders. <i>International Journal of Neuropsychopharmacology</i> , 2022, 25, 387-398.	1.0	4
108	Does N-acetylcysteine improve behaviour in children with autism?: A mixed-methods analysis of the effects of N-acetylcysteine. <i>Journal of Intellectual and Developmental Disability</i> , 2019, 44, 474-480.	1.1	3

#	ARTICLE	IF	CITATIONS
109	Gender, age at onset, and duration of being ill as predictors for the long-term course and outcome of schizophrenia: an international multicenter study. <i>CNS Spectrums</i> , 2022, 27, 716-723.	0.7	3
110	Adjunctive <i>Garcinia mangostana</i> Linn. (Mangosteen) Pericarp for Schizophrenia: A 24-Week Double-blind, Randomized, Placebo Controlled Efficacy Trial: Péricarpe de <i>Garcinia mangostana</i> Linn (mangoustan) pour la schizophrénie : un essai d'efficacité de 24 semaines, à double insu, randomisé et contrôlé par placebo. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 354-366.	0.9	3
111	Protocol update and statistical analysis plan for CADENCE-BZ: a randomized clinical trial to assess the efficacy of sodium benzoate as an adjunctive treatment in early psychosis. <i>Trials</i> , 2019, 20, 203.	0.7	2
112	Common effects of bipolar disorder medications on expression quantitative trait loci genes. <i>Journal of Psychiatric Research</i> , 2022, 150, 105-112.	1.5	2
113	Mixed Methods Thematic Analysis of a Randomised Controlled Trial of Adjunctive Mitochondrial Agents for Bipolar Depression. <i>Clinical Psychopharmacology and Neuroscience</i> , 2022, 20, 300-310.	0.9	2
114	Integrative Analyses of Transcriptomes to Explore Common Molecular Effects of Antipsychotic Drugs. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7508.	1.8	2
115	Fostering early and mid-career research in affective disorders. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 387-388.	1.3	1
116	Minocycline for the treatment of mental health and neurological conditions: study protocol of a systematic review and meta-analysis. <i>BMJ Open</i> , 2020, 10, e035080.	0.8	1
117	The Added Burden of Personality Disorder on Subsidized Australian Health Service Utilization Among Women With Mental State Disorder. <i>Frontiers in Global Women S Health</i> , 2021, 2, 615057.	1.1	1
118	Influence of childhood trauma on the treatment outcomes of pharmacological and/or psychological interventions for adolescents and adults with bipolar disorder: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2021, 11, e044569.	0.8	1
119	Baseline serum amino acid levels predict treatment response to augmentation with N-acetylcysteine (NAC) in a bipolar disorder randomised trial. <i>Journal of Psychiatric Research</i> , 2021, 142, 376-383.	1.5	1
120	Considerations when selecting pharmacotherapy for nicotine dependence. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 245-250.	0.9	0
121	In response to "There is no meta-analytic evidence of blueberries improving cognitive performance or mood". <i>Brain, Behavior, and Immunity</i> , 2020, 85, 193.	2.0	0
122	Cognitive insight, medication adherence and methamphetamine cessation in people enrolled in a pharmacotherapy trial for methamphetamine use. <i>Journal of Substance Abuse Treatment</i> , 2021, 130, 108473.	1.5	0
123	A placebo-controlled, randomised pilot trial of N-acetylcysteine or placebo for cessation of tobacco smoking. <i>European Neuropsychopharmacology</i> , 2021, 53, 120-126.	0.3	0